Susceptibility to simian immunodeficiency virus ex vivo predicts outcome of a prime-boost vaccine after SIVmac239 challenge

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 2, 2009, Pages 162-169

  Ochieng, Washingtone ^a,c   Sauermann, Ulrike ^a   Schulte, Reiner ^a   Suh, You Suk ^a,b   Kim, Kwang Soon ^b   Sung, Young C ^b   Hunsmann, Gerhard ^a   Stahl Hennig, Christiane ^a   Sopper, Sieghart ^a  

^a GERMAN PRIMATE CENTER   (Germany)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Correlate of protection; HIV; Immune response; Immunization; In vitro replication

Indexed keywords

GAMMA INTERFERON;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNIZATION; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

ANIMALS; CELLS, CULTURED; CLINICAL LABORATORY TECHNIQUES; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 70349676021     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b22f4a     Document Type: Article

References (43)

1. Malkevitch NV, Patterson LJ, Aldrich MK, et al. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology. 2006; 353:83-98.
2. Zhao J, Lou Y, Pinczewski J, et al. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr- SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine. 2003;21: 4022-4035.
3. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654-665.
4. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunode- ficiency virus type 1 gag gene. J Virol. 2003;77:6305-6313.
5. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331-335.
6. Suh YS, Park KS, Sauermann U, et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmacmacaque model. Vaccine. 2006;24:1811-1820.
7. Barouch DH, Santra S, Kuroda MJ, et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol. 2001;75:5151-5158.
8. Robinson HL, Montefiori DC, Villinger F, et al. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology. 2006;352:285-294.
9. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med. 2007;204:1405-1416.
10. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNAand modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol. 2006;80:4717-4728.
11. Petrovas C, Price DA, Mattapallil J, et al. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood. 2007;110: 928-936.
12. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science. 2007;318:1048-1049.
13. Thongcharoen P, Suriyanon V, Paris RM, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr. 2007;46:48-55.
14. Zhou Q, Hidajat R, Peng B, et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV (mac251). Vaccine. 2007;25:8021-8035.
15. Wilson NA, Reed J, Napoe GS, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol. 2006;80:5875-5885.
16. Chung C, Lee W, Loffredo JT, et al. Not all cytokine-producing CD8+ Tcells suppress simian immunodeficiency virus replication. J Virol. 2007; 81:1517-1523.
17. Walker CM, Erickson AL, Hsueh FC, et al. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J Virol. 1991;65: 5921-5927.
18. Walker CM, Moody DJ, Stites DP, et al. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986;234: 1563-1566.
19. Mackewicz CE, Craik CS, Levy JA. The CD8+ cell noncytotoxic anti- HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci U S A. 2003;100:3433-3438.
20. Stranford SA, Ong JC, Martinez-Marino B, et al. Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc Natl Acad Sci U S A. 2001;98:597-602.
21. Torres KJ, Gutierrez F, Espinosa E, et al. CD8+ cell noncytotoxic anti- HIV response: restoration by HAART in the late stage of infection. AIDS Res Hum Retroviruses. 2006;22:144-152.
22. Castelli JC, Deeks SG, Shiboski S, et al. Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals. Blood. 2002;99:4225-4227.
23. Geiben-Lynn R, Kursar M, Brown NV, et al. Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines. J Virol. 2001;75:8306-8316.
24. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 2002;415:335-339.
25. Friedrich TC, Dodds EJ, Yant LJ, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med. 2004;10:275-281.
26. Goldstein S, Brown CR, Dehghani H, et al. Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication. J Virol. 2000;74: 9388-9395.
27. Seman AL, Pewen WF, Fresh LF, et al. The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodefi- ciency virus in vitro is predictive of the rate of progression to AIDS in vivo. J Gen Virol. 2000;81:2441-2449.
28. Castillo RC, Arango-Jaramillo S, John R, et al. Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. J Infect Dis. 2000;181:897-903.
29. Schulte R, Suh YS, Sauermann U, et al. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. Virology. 2009;383: 300-309.
30. Fridholm H, Everitt E. Rapid and reproducible infectivity end-point titration of virulent phage in a microplate system. J Virol Methods. 2005; 128:67-71.
31. Hofmann-Lehmann R, Swenerton RK, Liska V, et al. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res Hum Retroviruses. 2000;16:1247-1257.
32. Killian MS, Ng S, Mackewicz CE, et al. A screening assay for detecting CD8+ cell non-cytotoxic anti-HIV responses. J Immunol Methods. 2005; 304:137-150.
33. Stahl-Hennig C, Suh YS, Park KS, et al. Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins. J Med Primatol. 2007;36: 195-205.
34. Muhl T, Krawczak M, Ten Haaft P, et al. MHC class I alleles influence setpoint viral load and survival time in simian immunodeficiency virusinfected rhesus monkeys. J Immunol. 2002;169:3438-3446.
35. Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science. 2006; 312:1530-1533.
36. O'Connor DH, Mothe BR, Weinfurter JT, et al. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol. 2003; 77:9029-9040.
37. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med. 2003;9:928-935.
38. Goletti D, Macchia I, Leone P, et al. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. Med Sci Monit. 2006;12:BR330-BR340.
39. Mattapallil JJ, Douek DC, Buckler-White A, et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med. 2006;203:1533-1541.
40. Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol. 2005;79:15547-15555.
41. Staprans SI, Barry AP, Silvestri G, et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIVenvelope protein. Proc Natl Acad Sci U S A. 2004; 101:13026-13031.
42. Kemball CC, Lee ED, Szomolanyi-Tsuda E, et al. Costimulation requirements for antiviral CD8+ T cells differ for acute and persistent phases of polyoma virus infection. J Immunol. 2006;176:1814-1824.
43. Kemball CC, Lee ED, Vezys V, et al. Late priming and variability of epitope-specific CD8+ T cell responses during a persistent virus infection. J Immunol. 2005;174:7950-7960.